Pinewood Codeïne Linctus

Product Beschrijving

1. Classification and Chemical Overview

Pinewood Codeine Linctus is a single-constituent, licensed oral liquid pharmaceutical preparation manufactured in Ireland and distributed extensively throughout the United Kingdom by Pinewood Laboratories Ltd (part of the Wockhardt group). Chemically designated as $(5R,6S,9R,13S,14R)\text{-3-methoxy-17-methyl-4,5-epoxymorphin-6-ol phosphate hemihydrate}$, codeine phosphate is a naturally occurring phenanthrene alkaloid obtained from the opium poppy (Papaver somniferum) or semi-synthetically methylated from morphine. Structurally, it consists of a rigid pentacyclic morphinan core with an ether bridge between carbon-4 and carbon-5, an aromatic A-ring bearing a methoxy moiety at carbon-3 (which drastically blunts baseline $\mu$-opioid receptor affinity relative to morphine), a cyclohexenol C-ring with an allylic hydroxyl at carbon-6, and a tertiary $N$-methylated nitrogen bridge. Its empirical molecular formula as the hemihydrate phosphate salt is $\text{C}_{18}\text{H}_{21}\text{NO}_3\cdot\text{H}_3\text{PO}_4\cdot\frac{1}{2}\text{H}_2\text{O}$, with an average molecular weight of $406.4\text{ g/mol}$ (unconjugated codeine base: $299.36\text{ g/mol}$).

Standard pharmaceutical presentations of Pinewood Codeine Linctus present as a clear, viscous, pale-straw or yellowish syrup formulated for oral administration. Standard packaging consists of an amber glass or polyethylene terephthalate (PET) bottle containing either $200\text{ mL}$ of $500\text{ mL}$ of liquid. The nominal concentration is $15\text{ mg}$ of codeine phosphate per $5\text{ mL}$ of linctus ($3\text{ mg/mL}$). A single $200\text{ mL}$ bottle delivers a cumulative dose of $600\text{ mg}$ of codeine phosphate, while a $500\text{ mL}$ stock dispensing bottle contains $1,500\text{ mg}$. Non-active pharmaceutical excipients include sucrose (syrup base), liquid glucose, glycerol (E422), ethanol ($96\%$), sodium benzoate (E211), citric acid monohydrate (E330), and purified water.

Within the United Kingdom regulatory framework:

• Historic Pharmacy (P) Status and Reclassification: Codeine linctus was historically classified as a Pharmacy (P) medicine, legally permitting sale over the counter by or under the direct supervision of a registered pharmacist for the treatment of dry, unproductive cough. However, widespread non-medical use, physical dependence, organized pharmacy diversion, and the proliferation of illicit sales through unregulated online pharmacies led to a decisive regulatory intervention:

  • Following an extensive national public safety consultation, the Medicines and Healthcare products Regulatory Agency (MHRA) officially reclassified all oral codeine-containing linctus medicines as Prescription Only Medicines (POM) in February 2024.

  • Over-the-counter retail sale is prohibited across the UK. Supply is restricted strictly to dispensing against a valid prescription issued by an authorized healthcare practitioner.

• Controlled Drug Scheduling: Under the Misuse of Drugs Act 1971, codeine is a Class B controlled substance. Under the Misuse of Drugs Regulations 2001, codeine linctus ($15\text{ mg}/5\text{ mL}$ in combination with non-controlled excipients) is categorized under Schedule 5 (CD Inv P / CD Inv POM), which exempts it from statutory Safe Custody register-logging requirements, but leaves it subject to all baseline POM and Class B possession and distribution statutes.

• NHS Formulary Positioning: Listed in the British National Formulary (BNF) and the NHS Drug Tariff; however, routine prescription on NHS prescription forms (FP10) is actively discouraged by primary care integrated care boards (ICBs) due to clinical guidelines deeming opioid cough suppressants obsolete and high-risk.

In contemporary forensic toxicology and community addiction monitoring, Pinewood Codeine Linctus represents the primary domestic UK pharmaceutical preparation diverted for the recreational preparation of “lean,” “purple drank,” or “dirty sprite.” Street or darknet transactions involving Pinewood bottles routinely command high black-market premiums. This demand has precipitated a parallel illicit market of counterfeit bottles filled with generic cough syrups spiked with illicitly manufactured synthetic opioids—principally nitazene analogues (e.g., isotonitazene, protonitazene, metonitazene)—or designer benzodiazepines (e.g., bromazolam), presenting catastrophic risks of acute, fatal respiratory failure.

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of Pinewood Codeine Linctus is defined by its role as an in vivo metabolic prodrug that produces central antitussive, analgesic, sedative, and respiratory-depressant actions through converted morphine:

• The Prodrug Paradigm and CYP2D6 Bioactivation: Intact codeine ($3\text{-O-methylmorphine}$) possesses very low intrinsic affinity for human $\mu$-opioid receptors (approximately $200\text{-fold}$ lower affinity than morphine, with negligible direct agonist efficacy). To exert biologically meaningful central actions, codeine must undergo metabolic bioactivation via hepatic cytochrome P450 2D6 (CYP2D6)-mediated $O$-demethylation to yield free morfine. Converted morphine accounts for the vast majority of its central neurochemical effects.

• Central Medullary Antitussive Mechanism: Codeine suppresses the cough reflex through direct depressant action within the nucleus tractus solitarii of the medulla oblongata:

  • Converted morphine and parent codeine bind to opioid receptors within the medullary cough-regulatory network.

  • Research indicates codeine also interacts with distinct, non-opioid $\sigma$-receptors ($\sigma_1$ en $\sigma_2$) within the brainstem, which contribute to the elevation of the threshold of the sensory vagal cough center.

  • This suppresses efferent neuro-motor triggers to the diaphragm, intercostal muscles, and larynx, dampening the frequency and intensity of non-productive coughing paroxysms.

• Postsynaptic $\mu$-Opioid (MOP) Receptor Signal Transduction: Converted morphine acts as a full agonist at human $\mu$-opioid receptors located throughout the dorsal horn of the spinal cord, periaqueductal gray, thalamus, and limbic circuits:

  • Agonism of $\mu$-receptors couples to pertussis toxin-sensitive heterotrimeric inhibitory $G_{\alpha i/o}$ proteins.

  • Receptor activation triggers the dissociation of the $G_{\beta\gamma}$ subunit, which directly inhibits presynaptic voltage-gated N-type calcium ($Ca^{2+}$) channels, halting the exocytosis of nociceptive neurotransmitters (substance P, glutamate, and CGRP).

  • Simultaneously, it opens postsynaptic G-protein-coupled inwardly rectifying potassium (GIRK) channels, driving massive intracellular potassium efflux. The resulting hyperpolarization stabilizes the resting membrane potential below firing thresholds, interrupting ascending sensory and nociceptive signaling.

• Respiratory Depression Dynamics: Within the pontomedullary respiratory pacemakers—specifically the pre-Bötzinger complex and the parabrachial/Kölliker-Fuse nuclei—activation of $\mu$-opioid receptors blunts the sensitivity of central chemoreceptors to elevations in arterial carbon dioxide ($\text{PaCO}_2$) and reductions in arterial oxygen ($\text{PaO}_2$). This concentration-dependent suppression of automatic respiratory pacing causes decreased tidal volumes and severe bradypnea.

• Enteric Nervous System Arrest: Codeine directly stimulates $\mu$– and $\kappa$-opioid receptors on cholinergic interneurons in the myenteric (Auerbach’s) and submucosal (Meissner’s) plexuses of the gut. This inhibits acetylcholine and vasoactive intestinal peptide (VIP) release, arresting propulsive peristalsis, increasing internal anal and ileocecal sphincter tone, and stimulating fluid absorption, resulting in profound, unremitting constipation.

3. Approved UK Clinical Indications and Therapeutic Scope

Where formally prescribed in the United Kingdom, Pinewood Codeine Linctus possesses an exceptionally narrow, specialized licensed therapeutic scope:

• Symptomatic Relief of Dry, Painful, Unproductive Cough:

  • Indicated for the short-term symptomatic relief of dry, hacking, non-productive cough in adults aged 18 years and older when non-opioid alternatives have failed.

  • Standard Adult Dosing: $5\text{ to }10\text{ mL}$ ($15\text{ to }30\text{ mg}$ codeine phosphate) taken orally three to four times daily as clinically indicated.

  • Ceiling Dosing: A maximum single dose of $10\text{ mL}$ ($30\text{ mg}$) and a maximum cumulative daily ceiling of $40\text{ mL}$ ($120\text{ mg}$ codeine phosphate) in any 24-hour period.

  • Duration Limit: Prescriptions must not exceed a maximum duration of 3 to 5 days. If symptoms persist, clinical re-evaluation is mandated to exclude underlying malignant or infectious pulmonary pathology.

• Strict Contraindication in Paediatrics (<18 Years):

  • Following historic MHRA drug safety reviews and European Medicines Agency (EMA) referrals, all codeine-containing medications for cough and cold are strictly contraindicated in children and adolescents under 18 years of age. This restriction was introduced due to catastrophic, fatal cases of respiratory arrest in pediatric patients identified post-mortem as CYP2D6 ultra-rapid metabolizers.

Clinical Positioning and NICE Guidance

National Institute for Health and Care Excellence (NICE) guidelines and Clinical Knowledge Summaries (CKS: Cough) explicitly advise against the use of codeine-containing cough suppressants for acute cough. Systematic reviews confirm that evidence demonstrating superior clinical efficacy of codeine over placebo or non-opioid demulcents is negligible, whereas the risks of rapid physical tolerance, dependence, fatal accidental overdose, and respiratory compromise are substantial. First-line clinical interventions emphasize non-pharmacological demulcents (e.g., simple honey and lemon mixtures or glycerol-based non-medicated linctuses).

In unauthorized and recreational drug subcultures, Pinewood Codeine Linctus is heavily abused:

• “Lean” / “Purple Drank” Preparation: Recreational users mix substantial volumes of codeine linctus ($50\text{ to }200\text{ mL}$, delivering $150\text{ to }600\text{ mg}$ of codeine phosphate) into sweetened lemon-lime sodas or fruit juices, co-administering it with over-the-counter or prescribed first-generation sedating antihistamines (principally promethazine). Promethazine prevents codeine-induced nausea, blocks peripheral histamine-induced itching, and amplifies central sedative-dissociative euphoria.

• Opioid Self-Medication and Tapering: Misused by individuals with underlying opioid use disorders (OUD) to avoid the painful autonomic storms of acute heroin, methadone, or oxycodone withdrawal.

4. Pharmacokinetic Profile and Metabolic Fate

The pharmacokinetic parameters of Pinewood Codeine Linctus are defined by rapid liquid absorption, complex parallel hepatic biotransformation pathways, and clinical reliance on CYP2D6 pharmacogenetics:

Hepatic Metabolic Pathways

1. Glucuronidation (Major Route, $\sim 70\text{ to }80\%$): Direct Phase II conjugation catalyzed by UDP-glucuronosyltransferase UGT2B7 converts codeine to codeine-6-glucuronide (C6G). C6G possesses modest intrinsic $\mu$-opioid receptor affinity and contributes to systemic analgesia and sedation.

2. $O$-Demethylation via CYP2D6 (Bioactivation Route, $\sim 5\text{ to }10\%$): Catalyzes the cleavage of the 3-methoxy ether into free morfine. Converted morphine is subsequently metabolized by UGT2B7 into active morphine-6-glucuronide (M6G, a potent $\mu$-opioid agonist) and neurotoxic morphine-3-glucuronide (M3G).

3. $N$-Demethylation via CYP3A4 ($\sim 10\%$): Cleaves the tertiary nitrogen to yield norcodeine, an inactive metabolite.

The CYP2D6 Pharmacogenetic Trap

Because CYP2D6 is highly polymorphic across global populations, clinical response to Pinewood Codeine Linctus varies widely:

• Poor Metabolisers (PMs; $7\text{ to }10\%$ of Caucasian populations): Individuals possessing two non-functional CYP2D6 alleles (e.g., *3, *4, *5, *6). PMs are enzymatically incapable of bioactivating codeine into morphine. They derive virtually no antitussive, analgesic, or euphoric efficacy from the linctus, yet remain completely susceptible to codeine-induced constipation, nausea, and histamine-mediated adverse reactions.

• Intermediate Metabolisers (IMs): Display reduced enzymatic capacity; modest, often suboptimal clinical response.

• Extensive (Normal) Metabolisers (EMs): Standard therapeutic response; predictable, controlled generation of morphine.

• Ultra-Rapid Metabolisers (UMs; up to $10\%$ of Caucasians, up to $29\%$ of specific Middle Eastern and North African cohorts): Individuals harboring gene duplications or amplifications of functional CYP2D6 alleles (e.g., *1xN, *2xN). UMs clear codeine rapidly into massive, uncontrolled concentrations of circulating free morphine. In UMs, standard or sub-therapeutic doses ($15\text{ to }30\text{ mg}$) precipitate catastrophic, unexpected central respiratory depression, profound comatose stupor, and fatal apnea.

5. Physiological Effects and Adverse Event Spectrum

Therapeutic administration of Pinewood Codeine Linctus diminishes the urge to cough, dries upper airway secretions, and induces mild sedation. However, widespread $\mu$-opioid receptor activation and peripheral histamine release generate an extensive adverse event spectrum:

• Histaminergic and Cutaneous Reactions (Very Common, $\ge 1/10$):

  • Codeine acts as a direct, non-immunological secretagogue triggering mast cell degranulation. Ingestion of therapeutic or recreational doses drives acute systemic histamine release, presenting as intense generalized pruritus (itching), cutaneous facial flushing, urticaria, conjunctival injection, and bronchospasm (dangerous in asthmatics).

• Gastrointestinal and Autonomic Disruptions (Very Common to Common, $\ge 1/100$ to $\ge 1/10$):

  • Profound Constipation: Enteric $\mu$-opioid agonism halts intestinal motility, causes hard/impacted stools, and can precipitate fecal impaction or stercoral ulceration in chronic users.

  • Nausea and vomiting: Driven by direct chemical stimulation of dopamine $D_2$ en $\mu$-opioid receptors in the chemoreceptor trigger zone (CTZ) of the area postrema.

  • Xerostomia (dry mouth) and epigastric discomfort.

  • Sphincter of Oddi Spasm: Marked constriction of biliary and pancreatic sphincters elevates intrabiliary pressure, precipitating acute biliary colic or exacerbating acute pancreatitis.

• Central Nervous System and Neuropsychiatric Toxicity (Common):

  • Drowsiness, daytime somnolence, dizziness, lightheadedness, and cognitive clouding.

  • Euphoria (driving psychological reinforcement) or paradoxical dysphoria, restlessness, and anxiety.

  • Mental confusion and vivid hallucinations (disproportionately observed in elderly cohorts).

• Severe, Emergent and Life-Threatening Hazards (Overdose & Chronic Dependence):

  • Fatal Central Respiratory Depression: The primary cause of death in codeine poisoning. Blunting of the brainstem pre-Bötzinger complex results in severe bradypnea ($<8\text{ breaths/min}$), progressive cyanosis, stupor advancing to deep unarousable coma, respiratory acidosis, and fatal cardiac arrest.

  • Synergistic Depressant Collapse (“Lean” Toxicity): Co-ingestion of Pinewood Codeine Linctus alongside alcohol, benzodiazepines (e.g., diazepam, alprazolam), or sedating antihistamines (e.g., promethazine) synergistically suppresses pontine and medullary respiratory drive, exponentially increasing fatal poisoning rates.

  • Physical Dependence and Acute Opioid Withdrawal Syndrome: Continuous exposure exceeding 1 to 2 weeks drives neuroadaptation. Abrupt discontinuation precipitates a severe withdrawal syndrome:

    • Intense autonomic hyperactivity: sinus tachycardia, hypertension, diaphoresis, rhinorrhea, and lacrimation.

    • Gastrointestinal cramping, severe nausea, vomiting, and explosive diarrhea.

    • Piloerection (“cold turkey”), mydriasis, diffuse myalgias, severe restlessness, and unremitting insomnia.

  • The Counterfeit Nitazene Hazard: Bottles sold illicitly under counterfeit Pinewood labels frequently contain high-potency synthetic nitazene opioids (such as metonitazene or protonitazene). Nitazenes exhibit potencies tens to hundreds of times higher than morphine, precipitating sudden, refractory respiratory collapse that fails to respond to conventional single doses of naloxone.

6. Contraindications, Drug Interactions, and Clinical Precautions

Prescribing, dispensing, and emergency evaluation of Pinewood Codeine Linctus require adherence to opioid safety guidelines, pharmacogenetic screening, and respiratory risk stratification:

• Contraindications:

  • Known CYP2D6 Ultra-Rapid Metabolisers: Absolute contraindication due to the certainty of life-threatening morphine toxicity at standard doses.

  • Paediatric Age Under 18 Years: Absolute contraindication in all children and adolescents under 18 years of age.

  • Acute Respiratory Compromise: Absolute contraindication in acute respiratory depression, severe chronic obstructive pulmonary disease (COPD), respiratory failure, or acute severe asthma.

  • Paralytic Ileus or Obstructive Bowel Disease: Absolute contraindication due to the risk of precipitating toxic megacolon or bowel perforation.

  • Head Injury and Raised Intracranial Pressure (ICP): Opioid-induced hypoventilation causes $\text{CO}_2$ retention, driving cerebral vasodilation that dangerously spikes intracranial pressure.

  • Concurrent Monoamine Oxidase Inhibitors (MAOIs): Absolute contraindication during or within 14 days of MAOI therapy (risks hyperpyrexic crises and central collapse).

  • Pregnancy and Breastfeeding: Absolute contraindication during breastfeeding (morphine distributes into maternal milk, presenting severe risks of fatal neonatal apnea); chronic use during pregnancy precipitates neonatal opioid withdrawal syndrome (NOWS).

• Drug Interactions:

  • Central Nervous System Depressants (e.g., Alcohol, Benzodiazepines, Antipsychotics, Sedating Antihistamines): Synergistic, catastrophic depression of medullary ventilatory drive; co-ingestion is the primary driver of fatal recreational syrup overdoses.

  • CYP2D6 Inhibitors (e.g., Fluoxetine, Paroxetine, Bupropion, Quinidine): Blocks the metabolic conversion of codeine to active morphine, completely abolishing antitussive and analgesic efficacy while leaving adverse histaminergic and gastrointestinal side effects unopposed.

  • CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin, St John’s Wort): Accelerates clearance to inactive norcodeine, significantly blunting clinical efficacy.

  • Anticholinergic Agents (e.g., TCAs, Antihistamines, Antimuscarinics): Compounded paralytic burden on the gastrointestinal tract and bladder, substantially increasing the risk of paralytic ileus and acute urinary retention.

• Clinical Precautions and Emergency Overdose Management (“Red Flags”):

  • Acute Overdose Resuscitation Protocol: Patients presenting to NHS emergency departments (999/A&E) with the classic opioid toxidrome (bradypnea $<8\text{ breaths/min}$, pinpoint pupils [miosis], and coma/unresponsiveness) require immediate emergency stabilization:

    • Airway and Oxygenation: Prioritize airway patency, position in the recovery position, deliver high-flow oxygen, and support ventilation with bag-valve-mask or endotracheal intubation.

    • Targeted Naloxone Administration: Administer the opioid antagonist naloxone ($400\text{ mcg}$ IV initially, repeating or escalating to $800\text{ mcg}$ to $2\text{ mg}$ every 2 to 3 minutes up to $10\text{ mg}$ as clinically indicated to restore adequate spontaneous respiration).

    • Prolonged Observation Window: Because converted morphine and active glucuronides have elimination half-lives ($2\text{ to }3.5\text{ hours}$) that outlast intravenous naloxone ($30\text{ to }60\text{ minutes}$ duration of action), patients must be observed under continuous pulse oximetry and clinical monitoring for a minimum of 4 to 6 hours to detect and manage re-narcotization.

    • Nitazene Suspicion: In patients who ingested counterfeit Pinewood bottles containing synthetic nitazene opioids, massive cumulative doses of naloxone ($>4\text{ to }10\text{ mg}$ IV or continuous IV infusion) may be required to maintain ventilation.

  • Sugar Content in Diabetic Patients: Pinewood Codeine Linctus contains high concentrations of sucrose and liquid glucose; each $5\text{ mL}$ dose introduces a significant glycaemic load that must be accounted for in patients with diabetes mellitus.

  • Detoxification Protocols: Dependent individuals attempting to discontinue codeine linctus must not be stopped abruptly without clinical support. Management involves structured stabilization and gradual dose reduction using licensed oral opioid substitution therapy (e.g., buprenorphine or methadone) under NHS community addiction recovery services.

  • Driving Safety Warning: Codeine impairs mental alertness and reaction times. Under Section 5A of the Road Traffic Act 1988, driving with specified controlled drugs in the blood above statutory limits is an offence; while a statutory medical defense exists for patients taking medications strictly as prescribed, patients must be explicitly advised not to drive if their driving skills are impaired.

Aanvullende Informatie